

DOCKET NO.: ALLE004-100
(17614)

PATENT

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method of treating a botulinum toxin intoxication in a mammal, ~~said the~~ method comprising the step of administering to the [[a]] mammal an effective amount of a glycosylated inactive botulinum toxin

wherein the effective amount of the glycosylated inactive botulinum toxin is an amount of glycosylated inactive botulinum toxin sufficient to compete with an active botulinum toxin for binding to a cell surface receptor, translocation through an endosomal membrane, cleavage of a SNAP-25 protein, cleavage of a synaptobrevin (VAMP) or cleavage of a syntaxin, thereby reducing the ability of the active botulinum toxin to intoxicate a neuron.

- 2-4. (canceled)

5. (currently amended) The method of ~~claim 1~~ claim 76 wherein the mutated light chain glycosylated inactive botulinum toxin comprises a light chain having the amino acid sequence set forth in SEQ ID NO:4.

6. (previously presented) The method of claim 1 wherein the glycosylated inactive botulinum toxin has a reduced antigenicity.

7. (currently amended) The method of ~~claim 6~~ claim 77 wherein the mutated heavy chain glycosylated inactive botulinum toxin has a is mutated in the Hc region.

8. (canceled)

DOCKET NO.: ALLE004-100
(17614)

PATENT

9. (previously presented) The method of claim 1 wherein the glycosylated inactive botulinum toxin is glycosylated chemically.
10. (previously presented) The method of claim 1 wherein the glycosylated inactive botulinum toxin is glycosylated by expression of the inactive botulinum toxin in a eukaryotic expression system.
11. (original) The method of claim 10 wherein the eukaryotic expression system is a baculovirus expression system.
- 12-17. (canceled)
18. (currently amended) The method of ~~claim 1~~ claim 21 or 80 wherein administration of the glycosylated inactive botulinum toxin ~~rescue agent~~ is administered orally.
19. (currently amended) The method of ~~claim 1~~ claim 21 or 80 wherein administration of the glycosylated inactive botulinum toxin ~~rescue agent~~ is administered intravenously.
20. (currently amended) The method of ~~claim 1~~ claim 21 or 80 wherein administration of the glycosylated inactive botulinum toxin ~~rescue agent~~ is administered locally.
21. (currently amended) The method of claim 1 wherein the glycosylated inactive botulinum toxin ~~rescue agent~~ is administered after to the mammal after an exposure to ~~has become intoxicated with a~~ an active botulinum toxin.
- 22-74. (canceled)

**DOCKET NO.: ALLE004-100
(17614)**

PATENT

75. (new) The method of claim 1 wherein the glycosylated inactive botulinum toxin has a mutated light chain.
76. (new) The method of claim 75 wherein the mutated light chain is mutated in the zinc binding motif.
77. (new) The method of claim 1 wherein the glycosylated inactive botulinum toxin has a mutated heavy chain.
78. (new) The method of claim 77 wherein the mutated heavy chain is mutated in the Hn region.
79. (new) The method of claim 1 wherein the glycosylated inactive botulinum toxin is selected from the group consisting of a botulinum toxin serotype A, a botulinum toxin serotype B, a botulinum toxin serotype C1, a botulinum toxin serotype D, a botulinum toxin serotype E, a botulinum toxin serotype F and a botulinum toxin serotype G.
80. (new) The method of claim 1 wherein the glycosylated inactive botulinum toxin is administered to the mammal before an exposure to an active botulinum toxin.